In all PTR patients, 7/66 (10.6%) have an early death, including 5/28 (17.9%) in CBF‐AML group and 2/38 (5.3%) in non‐CBF‐AML group (P = .125, Table S2). Here, CEBPZ is linked to acute myeloid leukemia.